SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Ernexa Therapeutics is trending due to significant momentum from positive preclinical data on its ovarian cancer treatment, which has ignited a battle between aggressive bulls targeting a breakout and skeptics focused on the company's dilution history. The community is closely watching the stock's low float and high short interest, with many traders anticipating a potential squeeze while others express caution regarding the long timeline for human clinical trials.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is experiencing a surge in investor interest fueled by a strong revenue beat and strategic pivots toward industrial-scale photonics and AI hardware. The community remains highly active in debating the stock's potential for a parabolic short squeeze, closely monitoring institutional accumulation and recent technological deployment milestones.

Kopin Corp. engages in the development, manufacture and sale of wearable technologies which include components and systems. Its portfolio includes AMLCD, LCOS displays, OLED displays, ASIC, backlights, and optical lenses. The firm uses semiconductor material technology to design, manufacture and market its component products for use in military, enterprise and consumer electronic applications, training and simulation equipment and 3D metrology equipment. The company was founded by John C.C. Fan on April 23, 1984 and is headquartered in Westborough, MA.

Kopin Corp.

Kopin Corp

Kopin Corp is surging following a new multi-million dollar defense contract and strong community buzz surrounding its pivot into AI-driven optical interconnect technology. Investors are actively tracking the stock's move toward higher price levels as they discuss its potential role in addressing data center power bottlenecks alongside the broader AI infrastructure market.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors weigh strong earnings and significantly raised EBITDA guidance against ongoing geopolitical instability in the Strait of Hormuz. While some community members remain frustrated by price volatility and perceived market manipulation, others are aggressively accumulating shares, viewing the company as a long-term play on rising global LNG demand and supply chain constraints.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is experiencing high volatility as investors track rumors of a potential take-private bid by Trian Fund Management, fueling speculation about a short squeeze. The community is focused on the stock's long-term valuation, significant short interest, and international expansion plans as key catalysts to defend current levels.

Token Cat Ltd. operates as a holding company, which engages in the operation of an omni-channel automotive marketplace. It offers auto shows, group-purchase facilitation, and virtual dealership services. The company was founded by Wei Wen and Jian Chen Sun in 2010 and is headquartered in Beijing, China.

Token Cat Ltd. - ADR

TuanChe Ltd - ADR

TuanChe is seeing significant investor attention fueled by a low float, a pivot toward a crypto asset investment strategy, and a recent partnership announcement. The community is actively debating its potential for volatility, comparing it to other high-momentum Chinese small-caps and noting its thin trading structure.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing intense volatility as retail investors debate whether the current rally is a structural re-rating driven by AI-fueled memory demand or a speculative bubble prone to a sharp correction. The community remains deeply divided, with bulls pointing to fundamental AI tailwinds and potential supply chain disruptions at competitors, while bears warn of a looming technical reversal and excessive retail euphoria.

Ambiq Micro, Inc. engages in the provision of ultra-low power semiconductor solutions designed to address the significant power consumption challenges of general purpose and AI computing. It operates through the following geographical segments: China, Taiwan, Singapore, and Rest of the World. The company was founded by Scott Hanson, Dennis Sylvester, and David Blaauw on January 20, 2010 and is headquartered in Austin, TX.

Ambiq Micro Inc.

Ambiq Micro, Inc.

Ambiq Micro is seeing significant retail attention fueled by a strong growth narrative in ultra-low power edge AI and ongoing speculation regarding potential major partnerships. Investors are closely monitoring the company's thin liquidity and small market capitalization, sparking intense community debate over whether the stock will trigger a major short-term breakout or continue to see volatile price fluctuations.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is seeing heightened investor attention following a significant expansion of its sales force and the rollout of preferred formulary status for its VEVYE dry eye treatment at major pharmacies. While the community is actively debating the company's guidance and the potential for a short squeeze, many are focused on the long-term growth trajectory of its ophthalmic portfolio.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is facing significant volatility as investors weigh record-breaking revenue and a massive backlog against concerns over softer guidance and elevated capital expenditure requirements. The community remains deeply divided, with bulls pointing to the company's long-term utility in the AI infrastructure cycle, while bears are aggressively highlighting insider selling patterns and debt concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sangamo Therapeutics (SGMO) to Release Earnings on Monday

Sangamo Therapeutics (NASDAQ:SGMO) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Update

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) was the target of a significant increase in short interest in April. As of April 15th, there was short interest totaling 42,883,635 shares, an increase of 14.0% from the March 31st total of 37,605,702 shares. Based on an average daily...

Sangamo Therapeutics (NASDAQ:SGMO) Insider Sells $17,456.75 in Stock

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) insider Gregory Davis sold 69,827 shares of the stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of...

Sangamo Therapeutics (NASDAQ:SGMO) SVP Sells $89,944.92 in Stock

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) SVP Nathalie Dubois-Stringfellow sold 345,942 shares of Sangamo Therapeutics stock in a transaction on Tuesday, April 21st. The stock was...

Gregory Davis Sells 69,827 Shares of Sangamo Therapeutics (NASDAQ:SGMO) Stock

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) insider Gregory Davis sold 69,827 shares of the firm's stock in a transaction dated Wednesday, April 22nd. The shares were sold at an...

Sangamo Therapeutics (NASDAQ:SGMO) Lowered to Strong Sell Rating by Zacks Research

Zacks Research lowered shares of Sangamo Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Thursday...

HC Wainwright Has Negative Forecast for SGMO FY2026 Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Stock analysts at HC Wainwright dropped their FY2026 earnings per share estimates for shares of Sangamo Therapeutics in a research note issued...

Equities Analysts Issue Forecasts for SGMO FY2028 Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright reduced their FY2028 earnings per share estimates for shares of Sangamo Therapeutics in a report released on Thursday, April...

<ul class="summary-bullets"><li>PEPG fell after its Phase 2 Freedom 2 study showed no meaningful improvements in walking speed or hand strength at the starting dose of 5 mg/kg.</li><li>SGMO slipped after reporting a Q4 loss per share of $0.11 versus the expected loss of $0.05, even as revenue rose to $14.23 million from $7.55 million a year earlier.</li><li>PHR declined after cutting its FY27 revenue outlook to $510 million-$520 million from $545 million-$559 million, below analyst expectations of $552.1 million.</li></ul>Shares of PepGen (PEPG), Sangamo Therapeutics (SGMO), and Phreesia (PHR) were among the top premarket losers on Tuesday as investors reacted to muted functional trial results, a wider-than-expected loss, and a revenue outlook cut, prompting analyst downgrades.In early premarket trading on Tuesday, PEPG plunged 45%, SGMO fell 19%, and PHR slumped 27%.<h2 class="st-heading-2">PepGen Trial Shows No Functional Gains At Low Dose</h2>PepGen reported results from the lowest-dose cohort in its Phase 2 Freedom 2 study of PGN-EDODM1 in patients with myotonic dystrophy type 1, with investors focusing on the lack of functional improvement at the starting dose.The company said the therapy was generally well tolerated, with all adverse events mild or moderate and no serious adverse events reported. However, the company also said patients showed “no meaningful improvements” in walking speed or hand strength at the starting 5 mg/kg dose of PGN-EDODM1.PepGen said patients receiving the treatment showed an average 7.3% improvement on a disease-related molecular metric, compared with 6.8% in placebo patients, rising to 22.9% after excluding one outlier. The company expects results from the higher 10 mg/kg cohort in the second half of 2026, with cash expected to support operations into the second half of 2027.<h2 class="st-heading-2">Sangamo Loss Widens As Funding Outlook Weighs</h2>Sangamo Therapeutics reported a fourth-quarter (Q4) loss per share of $0.11, wider than analyst expectations for a loss of $0.05, even as revenue rose to $14.23 million from $7.55 million a year earlier.The company highlighted progress in its Fabry disease gene therapy program, saying it is “well advanced in the rolling submission of the BLA to the FDA under the Accelerated Approval pathway” following positive topline results from the registrational STAAR study.However, sentiment appeared pressured after the company said its 2026 expense outlook is “subject to our ability to secure adequate additional funding for our current operating plan.” Sangamo expects non-GAAP operating expenses of $110 million to $120 million in 2026.<h2 class="st-heading-2">Phreesia Guidance Cut Triggers Broker Downgrades</h2>Phreesia reported Q4 revenue of $127.1 million, slightly above analyst expectations of $126.6 million, while adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) rose to $29.4 million from $16.4 million a year earlier.Shares fell after the company lowered its fiscal 2027 revenue outlook to $510 million to $520 million, down from $545 million to $559 million, and below analyst expectations of $552.1 million. The company said, “Network solutions clients are committing lower spend levels for the second half of fiscal 2027 than we had anticipated last December.”Following the guidance cut, Baird downgraded the stock to ‘Neutral’ from ‘Outperform’ and reduced its price target to $10 from $25, saying “the magnitude of the follow-on impact exceeded expectations.” Truist Securities also downgraded the stock to ‘Hold’ from ‘Buy’ and lowered its price target to $11 from $24, citing “the meaningful reduction to the revenue outlook.”<h2 class="st-heading-2">How Do Retail Traders Feel About PEPG, SGMO And PHR?</h2>On Stocktwits, retail sentiment for PEPG, SGMO and PHR was ‘extremely bullish’ amid ‘extremely high’ message volume.Over the past year, PEPG has risen 186%, while SGMO has fallen 63% and PHR has declined 56%.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/unh-stock-below-buffett-entry-price-first-revenue-decline-30-years-ai/cZEPohoRINz">UNH Stock Slides Back Below Warren Buffett’s Entry Price As Annual Revenue Faces First Decline In 30 Years — AI May Be Long-Term Fix</a>

Why PEPG, SGMO, PHR Are Among Top Premarket Losers Today

However, retail sentiment on Stocktwits across all three firms was ‘extremely bullish’ amid ‘extremely high’ message volumes.  In early premarket trading on Tuesday, PEPG plunged 45%, SGMO fell 19%, and PHR slumped 27%

Equity

However, retail sentiment on Stocktwits across all three firms was ‘extremely bullish’ amid ‘extremely high’ message volumes.

Sangamo Therapeutics Q4 Earnings Call Highlights

Sangamo Therapeutics (NASDAQ:SGMO) executives used the company's fourth-quarter and full-year 2025 earnings call to highlight progress across its Fabry disease and neurology pipelines, while...

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The firm focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$0.00	--	--	N/A
Q4 '25	$0.01	-$0.11	-1318.84%	MISSED
Q3 '25	-$0.00	-$0.11	-24344.44%	MISSED
Q2 '25	-$0.01	-$0.08	-694.68%	MISSED
Q1 '25	-$0.12	-$0.14	-19.37%	MISSED

SGMO
Sangamo Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest SGMO News

SGMOSangamo Therapeutics Inc